12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Gemzar gemcitabine: Phase III data

Researchers at the University of Liverpool and colleagues reported data from the open-label, international Phase III ESPAC-3 trial in 1,088 patients with completely resected pancreatic cancer showing that there was no significant difference on the primary endpoint of median OS between standard of care Gemzar...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >